Interferon-alpha in chronic myeloid leukemia revisited: a long-term retrospective study in Central and Northern Moravia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F13%3A33117915" target="_blank" >RIV/61989592:15110/13:33117915 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/13:#0000486

Výsledek na webu

<a href="http://dx.doi.org/10.5507/bp.2012.068" target="_blank" >http://dx.doi.org/10.5507/bp.2012.068</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2012.068" target="_blank" >10.5507/bp.2012.068</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Interferon-alpha in chronic myeloid leukemia revisited: a long-term retrospective study in Central and Northern Moravia

Popis výsledku v původním jazyce

Aims We assessed long-term outcome of consecutive patients in chronic phase of chronic myeloid leukemia (CML) treated with interferon-alpha (INF-?) in Central and Northern Moravia between 1989 and 2006. Methods A retrospective study focused on the response, prognostic factors and side effects of INF-?. Results 118 patients (67 males and 51 females at a median age 50 years; range 18-71) were analyzed. The median follow-up was 82.6 months (12.4-212.6). Thirty-six patients (30.5%) achieved major cytogenetic response (CyR) in median of 18.3 months (3.7-47.3) and maintained it for median of 64.0 months (7.0-176.0). Sixty-one patients treated with INF-? for more than 12 months had overall survival (OS) 137.0 months (95% CI 117.6-156.4). Eighteen (29.5%) of them achieved complete CyR (CCyR). 109 patients discontinued the treatment with INF-? because of hematologic or cytogenetic resistance in 53 (48.7%), progression of CML in 31 (28.4%) and intolerance to INF-? in 17 (15.6%) patients. The per

Název v anglickém jazyce

Interferon-alpha in chronic myeloid leukemia revisited: a long-term retrospective study in Central and Northern Moravia

Popis výsledku anglicky

Aims We assessed long-term outcome of consecutive patients in chronic phase of chronic myeloid leukemia (CML) treated with interferon-alpha (INF-?) in Central and Northern Moravia between 1989 and 2006. Methods A retrospective study focused on the response, prognostic factors and side effects of INF-?. Results 118 patients (67 males and 51 females at a median age 50 years; range 18-71) were analyzed. The median follow-up was 82.6 months (12.4-212.6). Thirty-six patients (30.5%) achieved major cytogenetic response (CyR) in median of 18.3 months (3.7-47.3) and maintained it for median of 64.0 months (7.0-176.0). Sixty-one patients treated with INF-? for more than 12 months had overall survival (OS) 137.0 months (95% CI 117.6-156.4). Eighteen (29.5%) of them achieved complete CyR (CCyR). 109 patients discontinued the treatment with INF-? because of hematologic or cytogenetic resistance in 53 (48.7%), progression of CML in 31 (28.4%) and intolerance to INF-? in 17 (15.6%) patients. The per

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers-Olomouc

ISSN

1213-8118

e-ISSN

—

Svazek periodika

157

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

9

Strana od-do

248-256

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—